Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
NovoCure Ltd.
Merck Sharp & Dohme LLC
Incyte Corporation
Hoffmann-La Roche
AstraZeneca
AstraZeneca
AstraZeneca
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eli Lilly and Company
Daiichi Sankyo
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Pfizer
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
AstraZeneca
Eli Lilly and Company
Bristol-Myers Squibb
AstraZeneca
Merck Sharp & Dohme LLC
American Regent, Inc.
Hoffmann-La Roche
BeiGene
Eli Lilly and Company
NRG Oncology
Gilead Sciences
Novartis
Boehringer Ingelheim
EMD Serono
Merck Sharp & Dohme LLC
Checkpoint Therapeutics, Inc.
Spanish Lung Cancer Group
National Cancer Institute (NCI)
Boehringer Ingelheim
BeiGene
Novartis
Alliance for Clinical Trials in Oncology
BeiGene
Alliance for Clinical Trials in Oncology
EMD Serono
Mirati Therapeutics Inc.